Cue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) CEO Daniel R. Passeri purchased 30,000 shares of the business's stock in a transaction dated Monday, December 16th. The shares were acquired at an average cost of $1.03 per share, for a total transaction of $30,900.00. Following the acquisition, the chief executive officer now owns 164,578 shares of the company's stock, valued at approximately $169,515.34. The trade was a 22.29 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Cue Biopharma Stock Up 0.9 %
Shares of Cue Biopharma stock opened at $1.07 on Thursday. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.22 and a quick ratio of 2.22. Cue Biopharma, Inc. has a 1-year low of $0.45 and a 1-year high of $3.20. The business's fifty day moving average price is $1.32 and its two-hundred day moving average price is $1.05. The company has a market capitalization of $67.78 million, a P/E ratio of -1.19 and a beta of 1.66.
Institutional Investors Weigh In On Cue Biopharma
Several institutional investors have recently bought and sold shares of the stock. GSA Capital Partners LLP raised its position in shares of Cue Biopharma by 5.1% during the 3rd quarter. GSA Capital Partners LLP now owns 291,663 shares of the company's stock worth $221,000 after buying an additional 14,104 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Cue Biopharma by 3.3% during the third quarter. Geode Capital Management LLC now owns 508,827 shares of the company's stock valued at $385,000 after acquiring an additional 16,371 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in Cue Biopharma during the second quarter worth approximately $66,000. Good Life Advisors LLC lifted its position in Cue Biopharma by 23.1% in the third quarter. Good Life Advisors LLC now owns 400,000 shares of the company's stock worth $303,000 after purchasing an additional 75,000 shares during the period. Finally, Sigma Planning Corp boosted its stake in Cue Biopharma by 50.9% during the 3rd quarter. Sigma Planning Corp now owns 401,325 shares of the company's stock valued at $304,000 after purchasing an additional 135,295 shares in the last quarter. Institutional investors and hedge funds own 35.04% of the company's stock.
Cue Biopharma Company Profile
(
Get Free Report)
We recommended Palantir in 2021, now we’re recommending this...
From Behind the Markets | Ad
My research indicates there is only one investment that can meet AI's unprecedented demand for energy.
Click to get the name and ticker symbol
Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
